EKF Diagnostics Holdings PLC Trading update (5893E)
November 09 2020 - 1:00AM
UK Regulatory
TIDMEKF
RNS Number : 5893E
EKF Diagnostics Holdings PLC
09 November 2020
This announcement contains inside information
for the purposes of Article 7 of Regulation (EU) No 596/2014
(MAR)
EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Trading update
Full year performance to further exceed market consensus
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed
point-of-care business, announces that strong trading in October,
combined with expected orders for the remainder of the year, will
result in full year performance ahead of market expectations ,
which have already been revised upwards several times this
year.
A significantly improved trading in the core business in the
final quarter, along with continued orders for the PrimeStore MTM
COVID-19 sample collection device underpins the Board's confidence
of a strong full year performance.
EKF now expects to deliver Group revenues and adjusted EBITDA
for the year ending 31 December 2020 comfortably ahead of market
consensus, with expectations currently set at GBP60m for revenues
and adjusted EBITDA of GBP23m.
The persons responsible for arranging the release of this
Announcement on behalf of the Company are Julian Baines, CEO, and
Richard Evans, FD and COO respectively.
EKF Diagnostics Holdings plc www.ekfdiagnostics.com
Christopher Mills, Non-executive Chairman Tel: +44 (0) 29 2071 0570
Julian Baines, CEO
Richard Evans, FD & COO
N+1 Singer Tel: 020 7496 3000
Aubrey Powell / George Tzimas (Corporate
Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Limited Tel: +44 (0) 20 7933 8780 or ekf@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: +44 (0) 7980 541 893 / +44 (0) 7584
391 303
About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com
)
EKF is a leading point-of-care diagnostics and central
laboratory assay manufacturer with an estimated 80,000 hemoglobin,
hematocrit, HbA1c, glucose and lactate analyzers in regular use
across more than 100 countries. EKF specializes in developing tests
for use in anemia and diabetes diagnosis and management, as well as
providing a portfolio of reagents for use in clinical chemistry
analyzers.
About PrimeStore MTM
Global demand for the PrimeStore MTM sample containment device
has increased significantly due to COVID-19. The device was
invented in 2006 in preparation for a worldwide pandemic and is
designed to de-activate pathogen rapidly and stabilise the RNA for
up to four weeks with no requirement for cold storage. This
approach also allows samples to be tested by a greater number of
laboratories, as the handling risks for the deactivated virus are
reduced.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TSTFLFETLRLTIII
(END) Dow Jones Newswires
November 09, 2020 02:00 ET (07:00 GMT)
Ekf Diagnostics (LSE:EKF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ekf Diagnostics (LSE:EKF)
Historical Stock Chart
From Apr 2023 to Apr 2024